Positive survival data for Kite's Yescarta in B-cell lymphoma

15 June 2023
kite_large-jpg

US biotech major Gilead Sciences’ (Nasdaq|: GILD) Kite unit today announced that its CAR T-cell therapy helped patients with relapsed or refractory large B-cell lymphoma (LBCL) live longer than historic treatment.

Detailed results from the overall survival (OS) analysis of the landmark Phase III ZUMA-7 study of Yescarta (axicabtagene ciloleucel [axi-cel]) compared with historical standard of care (SOC) as initial treatment in the curative setting for patients with relapsed or refractory large B-cell lymphoma (R/R LBCL).

Axicabtagene ciloleucel is the first treatment in nearly 30 years to demonstrate a significant improvement in survival in this patient population.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology